Article
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
PLoS medicine - 1 Oct 2007
Cragg Mark S, Kuroda Junya, Puthalakath Hamsa, Huang David C S, Strasser Andreas
Abstract excerpt
BACKGROUND: The epidermal growth factor receptor (EGFR) plays a critical role in the control of cellular proliferation, differentiation, and survival. Abnormalities in EGF-EGFR signaling, such as mutations that render the EGFR hyperactive or cause overexpression of the wild-type receptor, have been found in a broad range of cancers, including carcinomas of the lung, breast, and colon. EGFR inhibitors such as...
Topics
- Apoptosis Regulatory Proteins
- Bcl-2-Like Protein 11
- Biphenyl Compounds
- Carcinoma, Non-Small-Cell Lung
- Cell Death
- Cell Line, Tumor
- Drug Synergism
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms